A medicine for transplant can raise the chance of infections
Accessible version
|
Cyclophosphamide is still helpful; patients should be watched for infections |
Post-transplantation cyclophosphamide is associated with increased bacterial infections |
For blood or marrow transplant, younger donors more helpful
Accessible version
|
Older adults with leukemia should get younger, matched donors, if possible |
Impact of Donor Age on Allogeneic Hematopoietic Cell Transplantation Outcomes in Older Adults with Acute Myeloid Leukemia |
Most older people who have AML benefit from transplant
Accessible version
|
Of adults older than 60 who needed BMT, fewer than 5% got BMT |
Age is no barrier for adults undergoing HCT for AML in CR1: contemporary CIBMTR analysis. |
Transplant can cure T-cell prolymphocytic leukemia
Accessible version
|
Blood and marrow transplant is an option for some people with rare leukemia |
Outcomes of allogeneic hematopoietic cell transplantation in T cell prolymphocytic leukemia: A contemporary analysis from the Center for International Blood and Marrow Transplant Research. |
Half-matched and cord blood transplants fight leukemia
Accessible version
|
Both help people who have acute leukemia but no matched donor |
Comparison of haploidentical and umbilical cord blood transplantation after myeloablative conditioning. |
For some people older than 50, transplant from young, matched donors is better than half-matched donors |
Study looked at ages and types of donors to treat people with acute leukemia |
Alternative donor transplantation for acute myeloid leukemia in patients aged ≥50 years: Young HLA-matched unrelated or haploidentical donor? |
Haplo transplant helps people with leukemia |
News may help people of all ethnicities get BMT sooner |
Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. |
Blood or marrow transplant helps treat leukemia after age 60 |
People older than 60 lived longer after getting BMT than chemo alone. |
Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): An alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study. |
Experimental medicine treats children with leukemia and MDS |
Treosulfan may be safer than a similar medicine before transplant. |
Treosulfan, fludarabine and low-dose total body irradiation for children and young adults with acute myeloid leukemia or myelodysplastic syndrome undergoing allogeneic hematopoietic cell transplantation: A prospective phase II trial of the Pediatric Blood and Marrow Transplant Consortium. |
Chemotherapy prep for transplant works for acute leukemia, but risks of relapse are higher |
People with acute leukemia who got only chemotherapy (chemo) to prepare them for transplant lived almost as long as people who got chemo plus radiation, but their risks for leukemia recurrence were higher. People had fewer side effects with chemo-only prep. |
Intravenous busulfan compared with total body irradiation pretransplant conditioning for adults with acute lymphoblastic leukemiaIntravenous busulfan compared with total body irradiation pretransplant conditioning for adults with acute lymphoblastic leukemia. |
Patients with myelodysplastic syndromes or acute myeloid leukemia may benefit from a standard preparative regimen |
Patients who got a standard preparative regimen were more likely to be cancer-free a year and a half after transplant than patients who got a reduced-intensity regimen. |
Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes |
Treatment helps children and teens with acute leukemia thrive after cord blood transplants |
The TCF treatment regimen before cord blood transplant helped young people with acute leukemia live longer. |
Umbilical cord blood transplantation in children with acute leukemia: Impact of conditioning on transplantation outcomes |
Early results suggest people live equally long after half-matched transplants using either peripheral blood or bone marrow |
Scientists followed people for two years after transplants for: Acute leukemias, myelodysplastic syndrome, and lymphomas. |
Mobilized peripheral blood stem cells versus unstimulated bone marrow as a graft source for T-cell—replete haploidentical donor transplantation using post-transplant cyclophosphamide |
A transplant from an unrelated donor can treat acute lymphoblastic leukemia |
New research may make it possible for more people with acute lymphoblastic leukemia (ALL) to get life-saving transplants.
In the past, a transplant using blood-forming cells from a sibling was the only well-tested transplant option.
New research shows that a transplant from an unrelated donor can help people with ALL live equally long as a transplant from a sibling.
|
Comparing outcomes of matched related donor and matched unrelated donor hematopoietic cell transplants in adults with B-cell acute lymphoblastic leukemia |
Cytogenetics predict transplant results in older patients with acute myeloid leukemia |
Cytogenetic testing can predict BMT outcomes in older patients with AML.
Transplant works for about 1 of every 3 older patients with AML. |
Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for International Blood and Marrow Transplant Research cohort analysis |
Less chronic GVHD after cord blood transplant for acute leukemia |
Patients had less chronic GVHD after cord blood transplants.
Patients who received ATG had less acute GVHD.
|
GVHD after umbilical cord transplantation for acute leukemia: An analysis of risk factors and effect on outcomes |
Blood or marrow transplant can work well to treat B-cell acute lymphoblastic leukemia for older patients |
Reduced-intensity BMT can work well for older patients with B-cell ALL.
For patients who had BMT when the disease was in the 1st complete remission, almost half (45%) were alive 3 years later.
|
Reduced intensity conditioned allograft yields favorable survival for older adults with B-Cell acute lymphoblastic leukemia: A CIBMTR analysis |
Transplant may help older patients with acute myeloid leukemia |
Reduced-intensity transplant is a good treatment option for some older patients with AML. |
Phase II study of allogeneic transplantation for older patients with acute myeloid leukemia in first complete remission using a reduced-intensity conditioning regimen: Results from Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502 |
More teens and young adults with ALL survive after blood or marrow transplant than in the past |
5-year survival increased over time in teens and young adults and in children. |
Survival improvements in adolescents and young adults after myeloablative allogeneic transplantation for acute lymphoblastic leukemia |
Allo transplant helps some older patients with AML |
Older patients (aged 65 years and older) with AML can get high dose chemo if they are healthy enough.
About half of the older patients who get high dose chemo go into remission. However, the disease usually comes back within a year.
About 40% of older patients in remission who get an allo transplant live at least 2 years.
It is important for patients to talk with their doctor about an allo transplant as soon as they find out they have AML.
|
To transplant or not: A dilemma for treatment of elderly AML patients in the twenty-first century |
Similar survival for leukemia patients receiving transplants from related vs. unrelated donors |
Patients with leukemia who get a transplant from a well matched unrelated donor or from an unrelated donor with a single mismatch should have similar survival to patients who have a related donor. |
Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemia |
Unrelated umbilical cord blood transplants equal to unrelated bone marrow in helping children with acute leukemia |
Children with acute leukemia who receive unrelated umbilical-cord blood transplants have outcomes equal to - or in some cases, better than - those treated with bone marrow. |
Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: A comparison study |